AMY1C
protein-codingamylase alpha 1C, the group of Amylases alpha
Gene summary
Amylases are secreted proteins that hydrolyze 1,4-alpha-glucoside bonds in oligosaccharides and polysaccharides, and thus catalyze the first step in digestion of dietary starch and glycogen. The human genome has a cluster of several amylase genes that are expressed at high levels in either salivary gland or pancreas. This gene encodes an amylase isoenzyme produced by the salivary gland. [provided by RefSeq, Jul 2008]
- AMY1
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~13.4 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
No GenCC data available for this gene.
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to AMY1C variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_001008219.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 0 | |||||
| missense | 9 | 9 | ||||
| nonsense | 0 | |||||
| start loss | 0 | |||||
| frameshift | 0 | |||||
| splice donor/acceptor (+/-2bp) | 0 | |||||
| Total | 0 | 0 | 9 | 0 | 0 | 9 |
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_001008220.1 | 10 | MANE Select | |
| Ensembl | ENSP00000481450.2 | 10 | MANE Select | |
| RefSeq | NP_001333709.1 | 10 | Standard | |
| Ensembl | ENSP00000359096.3 | 10 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Starch and sucrose metabolism - Homo sapiens (human)
- Carbohydrate digestion and absorption - Homo sapiens (human)
- Salivary secretion - Homo sapiens (human)
- Glycogen synthetase deficiency
- Glycogenosis, Type III. Cori disease, Debrancher glycogenosis
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000370079
- Coding exons
- 10
- Length
- 8285
- Individuals with no LoFs
- 122078
- Homozygous LoFs
- 1
- Heterozygous LoFs
- 1879
- Defined
- 123958
- p
- 0.00761
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | -0.503 | 46 | 37.4 | 1.23 | 0.00000200 | 3357 |
| Missense (PolyPhen) | 20 | 19.237 | 1.0397 | 1532 | ||
| Synonymous | 0.433 | 10 | 11.9 | 0.840 | 6.74e-7 | 916 |
| Loss of Function | 0.495 | 4 | 5.22 | 0.766 | 3.21e-7 | 281 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.0023 | 0.0021 | notable |
| Latino/Admixed American | 0.0060 | 0.0050 | notable |
| Ashkenazi Jewish | 0.0060 | 0.0052 | notable |
| East Asian | 0.0011 | 0.0011 | notable |
| Finnish | 0.0096 | 0.0087 | notable |
| European (Non-Finnish) | 0.013 | 0.011 | notable |
| South Asian | 0.0038 | 0.0035 | notable |
| Other | 0.0090 | 0.0077 | notable |
dbNSFP Gene Annotations
Source:
Recessive Scores
- pRec
- 0.376
Essentials
- Essential (CRISPR)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.906
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |